Biotech Values

[floblu14]

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
May 22, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--May 22, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online.

The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N-protein), which were announced in December 2024, and include new data on the population PK/PD and time to viral load negativity.

E-Poster Title: “Antiviral Treatment of RSV in Children: Virology and PK Results of a Randomized Double-Blind Placebo-Controlled International Trial of Zelicapavir (EDP-938)”
E-Poster Number: ID 1767
Date and Time: Available starting on May 26, 2025, at 8:00 a.m. Eastern European Summer Time/ 1:00 a.m. Eastern Daylight Time
E-Poster Location: Level 0, Main Floor or on the conference portal and the conference app
Presenter: John DeVincenzo, M.D.

A copy of the E-Poster will be available on Enanta’s website here. The scientific program for ESPID 2025 can be found here.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-data-its-phase-2-study